These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1461082)

  • 21. The effect of D-penicillamine on mitogen-induced human lymphocyte proliferation: synergistic inhibition by D-penicillamine and copper salts.
    Lipsky PE; Ziff M
    J Immunol; 1978 Mar; 120(3):1006-13. PubMed ID: 632576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cu(2+)-responsive bimodal (optical/MRI) contrast agent for cellular imaging.
    Jang JH; Bhuniya S; Kang J; Yeom A; Hong KS; Kim JS
    Org Lett; 2013 Sep; 15(18):4702-5. PubMed ID: 24015763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. D-penicillamine treatment of copper-associated hepatitis in Labrador retrievers.
    Fieten H; Dirksen K; van den Ingh TS; Winter EA; Watson AL; Leegwater PA; Rothuizen J
    Vet J; 2013 Jun; 196(3):522-7. PubMed ID: 23375251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The interactions of penicillamine with copper in vivo and the effect on hepatic metallothionein levels and copper/zinc distribution: the implications for Wilson's disease and arthritis therapy.
    McQuaid A; Lamand M; Mason J
    J Lab Clin Med; 1992 Jun; 119(6):744-50. PubMed ID: 1593220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The development of screening tests for D-penicillamine-like antirheumatic activity based on in vivo interactions with copper.
    Cashin CH; Lewis EJ; Burden T
    Br J Rheumatol; 1985 May; 24(2):137-46. PubMed ID: 3995211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MRI and oxidative stress markers in neurological worsening of Wilson disease following penicillamine.
    Ranjan A; Kalita J; Kumar V; Misra UK
    Neurotoxicology; 2015 Jul; 49():45-9. PubMed ID: 26004675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis.
    Hottinger AF; Fine EG; Gurney ME; Zurn AD; Aebischer P
    Eur J Neurosci; 1997 Jul; 9(7):1548-51. PubMed ID: 9240414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wilson's disease: assessment of D-penicillamine treatment.
    Van Caillie-Bertrand M; Degenhart HJ; Luijendijk I; Bouquet J; Sinaasappel M
    Arch Dis Child; 1985 Jul; 60(7):652-5. PubMed ID: 4026361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnetically coupled paramagnetic relaxation agents.
    Lester CC; Bryant RG
    Magn Reson Med; 1992 Apr; 24(2):236-42. PubMed ID: 1314929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the efficacy of d-penicillamine and trientine as copper chelators using an in vitro technique involving ovine red blood cells.
    Botha CJ; Naude TW; Swan GE; Guthrie AJ
    Onderstepoort J Vet Res; 1992 Sep; 59(3):191-5. PubMed ID: 1437021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of the superoxide dismutating activity of D-penicillamine copper.
    Lengfelder E; Elstner EF
    Hoppe Seylers Z Physiol Chem; 1978 Jun; 359(6):751-7. PubMed ID: 669584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circular dichroism and resonance Raman spectra of the Cu(II)-Cu(I) complex of D-penicillamine. The CuS(CYs) stretching mode in blue copper proteins.
    Tosi L; Garnier A
    Biochem Biophys Res Commun; 1979 Dec; 91(4):1273-9. PubMed ID: 526303
    [No Abstract]   [Full Text] [Related]  

  • 33. In vitro production and scavenging of hydrogen peroxide by D-penicillamine. Relationship to copper availability.
    Staite ND; Messner RP; Zoschke DC
    Arthritis Rheum; 1985 Aug; 28(8):914-21. PubMed ID: 4026887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. D-penicillamine-templated copper nanoparticles via ascorbic acid reduction as a mercury ion sensor.
    Lin SM; Geng S; Li N; Li NB; Luo HQ
    Talanta; 2016 May; 151():106-113. PubMed ID: 26946016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spatial investigation of the elemental distribution in Wilson's disease liver after d-penicillamine treatment by LA-ICP-MS.
    Hachmöller O; Zibert A; Zischka H; Sperling M; Groba SR; Grünewald I; Wardelmann E; Schmidt HH; Karst U
    J Trace Elem Med Biol; 2017 Dec; 44():26-31. PubMed ID: 28965585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure, properties, and function of a copper(I)-copper(II) complex of D-penicillamine: pentathallium(I) mu8-chloro-dodeca (D-penicillaminato)-octacuprate(I)hexacuprate(II) n-hydrate.
    Birker PJ; Freeman HC
    J Am Chem Soc; 1977 Oct; 99(21):6890-9. PubMed ID: 903530
    [No Abstract]   [Full Text] [Related]  

  • 37. Urinary copper excretion before and after oral intake of d-penicillamine in parents of patients with Wilson's disease.
    Vieira J; Oliveira PV; Juliano Y; Warde KR; Deguti MM; Barbosa ER; Carrilho FJ; Cancado EL
    Dig Liver Dis; 2012 Apr; 44(4):323-7. PubMed ID: 22169274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of D-penicillamine on copper retention in patients with primary billiary cirrhosis.
    Deering TB; Dickson ER; Fleming CR; Geall MG; McCall JT; Baggenstoss AH
    Gastroenterology; 1977 Jun; 72(6):1208-12. PubMed ID: 870369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cu
    Hu M; Chen J; Wang J; Zhang Y; Liu L; Morais PC; Bi H
    Biomater Sci; 2017 Oct; 5(11):2319-2327. PubMed ID: 29027548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One-pot preparation of hydrophilic manganese oxide nanoparticles as T
    Li J; Wu C; Hou P; Zhang M; Xu K
    Biosens Bioelectron; 2018 Apr; 102():1-8. PubMed ID: 29101783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.